Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Patent metadata

Field	Value
Publication number	US-9725450-B2
Application number	US-201514918655-A
Country	US
Kind code	B2
Filing date	Oct 21, 2015
Priority date	Jan 13, 2005
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

Provided herein are Aminopurine Compounds having the following structure:

wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

First claim

What is claimed is:

1. A compound having the formula (I):

or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is unsubstituted C 3-10 heterocycle;
R 2 is cyclohexyl substituted with one or more hydroxyl, cyano, tetrazolyl, triazolyl or imidazolyl groups; and
R 3 is aryl substituted with one or more halogens.

2. A compound of claim 1 wherein R 2 is cyclohexyl substituted with one or more hydroxyl or cyano groups.

3. A compound of claim 1 wherein R 3 is fluoro substituted aryl.

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, excipient or diluent.

5. The pharmaceutical composition of claim 4 suitable for oral, parenteral, mucosal, transdermal or topical administration.

6. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier, excipient or diluent.

7. The pharmaceutical composition of claim 6 suitable for oral, parenteral, mucosal, transdermal or topical administration.

8. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier, excipient or diluent.

9. The pharmaceutical composition of claim 8 suitable for oral, parenteral, mucosal, transdermal or topical administration.

Assignees

• Signal Pharm Llc

Inventors

• Clareen Steven
• Plantevin-Krenitsky Veronique
• Palanki Moorthy
• Satoh Yoshitaka

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/52

  Purines, e.g. adenine · CPC title

• C07D473/32 Primary

  Nitrogen atom · CPC title